Company Description
Maxygen dedicates itself to maximizing the potential of protein-based pharmaceuticals. The development-stage biotechnology company is creating...
Key Maxygen Financials
| Company Type | Public - NASDAQ (GM): MAXY Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $23.2 |
| 2005 Employees | 144 |
More Maxygen Financials (11 pages)
Latest Maxygen Jobs jobs by Indeed
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Maxygen's competition across multiple industries
Top Maxygen Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Maxygen Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Isaac Stein | Network | E-mail |
| CEO and Director | Russell J. Howard | Network | E-mail |
| COO | Elliot P. Goldstein | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Maxygen News
- Maxygen To Sell Hemophilia Treatment Program To Bayer Unit For $90 Million [InvesTrend] (03 Jul 2008 00:01:00 EDT)
- BioWorld Today July 3, 2008 [BioWorld Today] (03 Jul 2008 00:01:00 EDT)
- Briefing.com: Hourly In Play (R) - 23:00 ET [Briefing.com] (02 Jul 2008 23:01:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.